Billionaire Israel Englander Goes Big On These 3 Penny Stocks
Penny stocks, they divide market watchers like no other. Some investors avoid these tickers costing less than $ 5 each, as poor fundamentals or crushing headwinds could keep them from falling into landfills. On the other hand, penny stocks attract the more risk-tolerant. Not only does the great price mean you’re getting what you pay for, even a minor appreciation in the stock price can generate huge percentage gains as well. The implication? Important returns for investors: Based on the above, eliminating the long-term underperformance of penny stocks in search of gold can be a significant challenge. In this case, the activity of the legendary title collectors can be a source of inspiration. Among these Wall Street titans is Israel “Izzy” Englander. Englander is President, CEO and Co-Chief Investment Officer of Millennium Management, the hedge fund he founded in 1989. Speaking on his impressive record, he took the $ 35 million with which the fund has was created and turned them into $ 73 billion in assets under management. With that in mind, we used TipRanks’ database to find out what the analyst community has to say about the three-penny stocks that the Englander fund recently clawed back. In fact, each ticker only received buy notes. Not to mention substantial upside potential is also on the table.Kindred Biosciences (KIN) In hopes of bringing innovative biologics to veterinary medicine, Kindred Biosciences believes pets deserve the same kinds of medicines. safe and effective than humans. At $ 3.78, Wall Street pros believe its stock price might reflect the perfect entry point given all the company has to offer. English is one of KIN’s fans. During the second quarter, Millennium pulled the trigger on 821,752 shares. As for the value of this new position, it stands at $ 3,690,000. Cantor’s analyst Brandon Folkes also sings the health name praises. “KIN has a portfolio of very good assets that can generate significant value if brought to market,” Folkes explained. The analyst points out that there has been a shift in strategy and priorities over the past 12 months, but he believes that “the company’s pipeline of new animal health drugs will result in long-term value for them. shareholders above the levels reflected in the current share price ”. The company continues to advance its biologic programs, including IL-31 and IL-4R antibodies for canine atopic dermatitis, KIND-030 for parvovirus in dogs, and KIND-510a for the control of non-anemia. regenerative in cats, as well as According to Folkes, Folkes believes his partnerships help unlock value. In addition to the good news, Folkes sees its partnerships as helping unlock value. These partnerships include a manufacturing agreement with Vaxart for the manufacture of Vaxart’s oral vaccine candidate against COVID-19. To sum up, Folkes said, “With animal health companies trading at 4.5-8.5 times estimated revenue in 2021 and business development playing an important role in the long-term growth of these companies. large animal health companies, we believe that KIN’s pipeline offers a unique suite of significant revenue opportunities for large companies, if KIN can realize the potential of its pipeline. We believe KIN stock remains undervalued at current levels, and as 2020 progresses, we expect pipeline advances to drive the stock higher. To that end, Folkes assigns KIN an overweight (ie buy) with a price target of $ 11. If his thesis materializes, a potential gain of 191% over twelve months could be envisaged. (To see Folkes’ track record, click here) Other analysts disagree. With 4 buy reviews and no hold or sell, the word on the street is KIN is a strong buy. The average price target of $ 11.50 is more aggressive than Folkes’ and implies a potential upside of 208%. (See KIN Stock Analysis on TipRanks) Agenus Inc. (AGEN) Next on our list is Agenus, which is developing an immuno-oncology portfolio that includes checkpoint antibodies, cell therapies, vaccines and adjuvants. While the name, which changed hands for $ 4.02 apiece, has remained relatively unrecognized, some believe great things could be on the horizon. During the second quarter, Millenium made a major purchase. With 2,339,149 shares, the hedge fund’s new AGEN position is valued at $ 9,193,000. 5-star analyst Mayank Mamtani of B. Riley FBR was also impressed. On August 6, AGEN provided an update on the progress of its pipeline. Its main programs, AGEN2034 or balstilimab (bali; anti-PD1) and AGEN1884 or zalifrelimab (zali), are on track for separate BLA submissions, both in combination as well as bali as YE20 monotherapy, refractory / relapse all – occurring (r / r) cancer of the cervix. “It should be noted that in r / r cervical cancer, zali / bali is clinically risk-free and significantly differentiated from competing cell therapy approaches based on Merck’s Keytruda and / or TIL from Iovance; In addition, we consider that zali / bali serves as a fast and efficient BMY ipi / nivo tracker on several tumor types with a pricing option, a key strategic lever for AGEN to be deployed as it enters the market in 2021 ”, explained Mamtani. AGEN1181, its multi-T lymphocyte antibody and CTLA-4 which was engineered by Fc to overcome genetic polymorphism in the CD16 allele, produced a strong result in the phase 1 endometrial cancer trial MSS r / r. After a CR generated by the AGEN1181 1 mg / kg monotherapy dose, AGEN1181 0.3 mg in combination with zali had a RA with ~ 80% tumor shrinkage changes to CR, as evidenced by a PET scan. “We are encouraged by AGEN to identify the accelerated path to market by testing for refractory PD-1 melanoma as well as ‘cold’ tumors in MSI-stable endometrial and colorectal cancer, and hepatocellular carcinoma, possibly in one-arm phase 2 settings, as well as to realize the full longer-term potential in high prevalence tumor types such as NSCLC and prostate cancer. On this last point, AGEN’s intention to establish AGEN1181 as the preferred checkpoint inhibitor for combination therapy was recently validated by the AACR’20 summary demonstrating synergistic benefit with several therapeutic modalities, ”added Mamtani. With all of this in mind, Mamtani rates AGEN a buy with a target price of $ 8, which implies a 99% rise from current levels (to look at Mamtani’s track record, click here). Breakdown of consensus, he has been calm when it comes to another analyst activity. In the past three months, only 2 analysts have issued ratings. However, since they were both buys, the word on the street is that AGEN is a moderate buy. (See Agenus stock market analysis on TipRanks) Marinus (MRNS) Last but not least is Marinus, who works on neuropsychiatric therapies and is considered a leader in orphan seizure disorders. Currently at $ 1.76 each, several members of the street think it’s time for some action. Anglander stands squarely with the bulls on this one. The billionaire’s fund bought back 934,155 shares in the second quarter. Reflecting a new position, the property is valued at $ 2,373,000. Before a quick read of the data, Oppenheimer analyst Jay Olson is on board. Pivotal Phase 3 Marigold data for ganaxolone (GNX) in CDKL5 deficiency disorder (CDD) are scheduled to be released on any day. The patient’s last visit for this trial was in July, and the primary endpoint is reduction in seizure frequency over 17 weeks for GNX compared to placebo. “Data from previous open-label phase 2 trials show a reduction in seizure frequency of -44% on day 28 (N = 7) and -54% at 6 months (N = 4), suggesting durability and a low discontinuation rate of less than 10% in phase 3 MARIGOLD suggests favorable tolerability, ”commented Olson. However, Olson points out that this data release is “overshadowed by long-term value drivers.” The first of these is the pivotal phase 3 CSR trial of GNX, the design and dosage of which were confirmed at the EOP2 FDA meeting. The MRNS still expects to start the trial in Q3 2020. Olson noted: “We view the pivotal phase 3 design as similar to the positive phase 2 trial while benefiting from a longer dosing with 12 hours. exposure compared to 8 hours previously. MRNS expects high level data in 1H22. If that weren’t enough, the MRNS announced that patient screening has started for the phase 2 trial of GNX’s tuberous sclerosis complex (TSC), with the top reading scheduled for 1Q21 with l analysis of Allo-S biomarkers. Considering everything MRNS has going for it, Olson rates the stock as outperforming (i.e., buying) with a price target of $ 6. This suggests that stocks could rise 237% next year. (To look at Olson’s track record, click here) It turns out other analysts like what they see, too. Only buy ratings, 4 to be exact, have been received in the past three months, so the consensus rating is a strong buy. Additionally, the average price target of $ 6.50 indicates upside potential of 263%. (See Marinus Stock Analysis on TipRanks) For great ideas for trading penny stocks at attractive valuations, visit Top Stocks to Buy from TipRanks, a newly launched tool that brings together all the information about stocks from TipRanks .Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. This article originally appeared on TipRanks.